Alistair C Church
Overview
Explore the profile of Alistair C Church including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
13
Citations
184
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Wilson K, Buist H, Suveizdyte K, Liles J, Budas G, Hughes C, et al.
Pulm Circ
. 2020 Jun;
10(2):2045894020922810.
PMID: 32523684
Pulmonary arterial hypertension, group 1 of the pulmonary hypertension disease family, involves pulmonary vascular remodelling, right ventricular dysfunction and cardiac failure. Oxidative stress, through activation of mitogen-activated protein kinases is...
2.
Price L, Dimopoulos K, Marino P, Alonso-Gonzalez R, McCabe C, Kemnpy A, et al.
Thorax
. 2017 Sep;
72(11):1035-1045.
PMID: 28904006
Treatment of acute emergencies in patients with pulmonary arterial hypertension (PAH) can be challenging. In the UK and Ireland, management of adult patients with PAH is centred in eight nationally...
3.
Panagiotou M, Johnson M, Louvaris Z, Baker J, Church A, Peacock A, et al.
J Appl Physiol (1985)
. 2017 Jul;
123(4):851-859.
PMID: 28663381
Daily physical activity is reduced in precapillary pulmonary hypertension (PH), but the underlying mechanisms are inadequately explored. We sought to investigate clinical and physiological relations of daily physical activity and...
4.
Panagiotou M, Vogiatzis I, Jayasekera G, Louvaris Z, Mackenzie A, McGlinchey N, et al.
Clin Physiol Funct Imaging
. 2017 Feb;
38(2):254-260.
PMID: 28168802
Background: Non-invasive methods of measuring cardiac output are highly desirable in pulmonary arterial hypertension (PAH). We therefore sought to validate impedance cardiography (ICG) against thermodilution (TD) and cardiac magnetic resonance...
5.
Panagiotou M, Church A, Johnson M, Peacock A
Eur Respir Rev
. 2017 Jan;
26(143).
PMID: 28096284
Pulmonary vascular and cardiac impairment is increasingly appreciated as a major adverse factor in the natural history of interstitial lung disease. This clinically orientated review focuses on the current concepts...
6.
Panagiotou M, Vogiatzis I, Louvaris Z, Jayasekera G, McKenzie A, McGlinchey N, et al.
Eur Respir J
. 2017 Jan;
49(1).
PMID: 28052962
No abstract available.
7.
Panagiotou M, Vogiatzis I, Louvaris Z, Jayasekera G, Mackenzie A, McGlinchey N, et al.
Eur Respir J
. 2016 Sep;
48(4):1224-1227.
PMID: 27587562
No abstract available.
8.
Brewis M, Church A, Johnson M, Peacock A
Eur Respir J
. 2015 Aug;
46(5):1378-89.
PMID: 26293503
Pulmonary hypertension (PH) due to lung disease (World Health Organization (WHO) group 3) is common, but severe PH, arbitrarily defined as mean pulmonary artery pressure ≥35 mmHg is reported in...
9.
Menni C, Graham D, Kastenmuller G, Alharbi N, Alsanosi S, McBride M, et al.
Hypertension
. 2015 Jun;
66(2):422-9.
PMID: 26034203
High blood pressure is a major contributor to the global burden of disease and discovering novel causal pathways of blood pressure regulation has been challenging. We tested blood pressure associations...
10.
Church A, Martin D, Wadsworth R, Bryson G, Fisher A, Welsh D, et al.
Am J Physiol Lung Cell Mol Physiol
. 2015 May;
309(4):L333-47.
PMID: 26024891
The p38 mitogen-activated protein kinase (MAPK) system is increasingly recognized as an important inflammatory pathway in systemic vascular disease but its role in pulmonary vascular disease is unclear. Previous in...